Syndax Pharmaceuticals SNDX Business Segments — Marketing And Advertising Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:MarketingAndAdvertisingExpense.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's business segments — marketing and advertising expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's business segments — marketing and advertising expense?
- Syndax Pharmaceuticals (SNDX) reported business segments — marketing and advertising expense of $7.72M in Q1 2026.
- How has Syndax Pharmaceuticals's business segments — marketing and advertising expense changed year-over-year?
- Syndax Pharmaceuticals's business segments — marketing and advertising expense decreased by 28.7% year-over-year, from $10.83M to $7.72M.
- What is the long-term trend for Syndax Pharmaceuticals's business segments — marketing and advertising expense?
- Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — marketing and advertising expense has grown at a 193.7% compound annual growth rate (CAGR), from $2.12M to $53.63M.
- What does business segments — marketing and advertising expense mean?
- This represents the expenditures dedicated to promoting and creating market awareness for the company's oncology products. It includes costs for medical education, sales force support, and promotional campaigns aimed at healthcare providers. This metric is critical for evaluating the company's commercialization strategy and the effectiveness of its market entry efforts.